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Fanconi anemia (FA) is a developmental and
cancer-predisposition syndrome caused by
mutations in genes controlling DNA interstrand
crosslink repair. Several FA proteins form a
ubiquitin ligase that controls monoubiquitina-
tion of the FANCD2 protein in an ATR-dependent
manner. Here we describe the FA protein
FANCI, identified as an ATM/ATR kinase sub-
strate required for resistance to mitomycin C.
FANCI shares sequence similarity with FANCD2,
likely evolving from a common ancestral gene.
The FANCI protein associates with FANCD2
and, together, as the FANCI-FANCD2 (ID) com-
plex, localize to chromatin in response to DNA
damage. Like FANCD2, FANCI is monoubiquiti-
nated and unexpectedly, ubiquitination of each
protein is important for the maintenance of
ubiquitin on the other, indicating the existence
of a dual ubiquitin-locking mechanism required
for ID complex function. Mutation in FANCI is
responsible for loss of a functional FA pathway
in a patient with Fanconi anemia complementa-
tion group I.
INTRODUCTION
The ability to sense and respond to DNA damage and DNA
replication stress is critical for cellular and organismal sur-
vival. A failure to properly respond to genotoxic stress can
lead to both developmental difficulties and tumorigenesis.
Cells have evolved a complex signal transduction pathway
that senses genotoxic stress and responds by activatingspecific types of repair, arresting the cell cycle and altering
transcription. At the core of this signal transduction path-
way are the ATM and ATR kinases (Bakkenist and Kastan,
2004; Bartek et al., 2004; Zhou and Elledge, 2000). These
kinases phosphorylate over 20 known proteins in response
to damage, including the Chk1 and Chk2 kinases. While
early theories on these pathways considered their major
role to be controlling cell cycle transitions, it is now clear
that they play critical roles in regulating essential functions
in both DNA replication and DNA repair.
One pathway regulated by ATM/ATR is the Fanconi
anemia (FA) crosslink repair pathway (Gurtan and D’Andrea,
2006). Patients with FA display multiorgan defects, and
most develop bone marrow failure in childhood (Butturini
et al., 1994; Fanconi, 1967; Schmid and Fanconi, 1978).
FA patients have a high incidence of hematological and
nonhematological malignancies, and their cells are hyper-
sensitive to DNA interstrand crosslinking agents such as
mitomycin C (MMC) (Alter et al., 2003). FA falls into 13
complementation groups, and 12 FA genes have been
cloned (Gurtan and D’Andrea, 2006; Reid et al., 2007;
Taniguchi and D’Andrea, 2006; Xia et al., 2006, 2007).
Eight of these proteins (all but D2, D1, J, and N) are sub-
units of an FA core complex, a nuclear E3 ubiquitin ligase
(Machida et al., 2006; Meetei et al., 2004). A key substrate
of this ligase is FANCD2, which is monoubiquitinated
on lysine 561 (Garcia-Higuera et al., 2001). It has been
hypothesized that there is another critical substrate for the
ligase in addition to FANCD2, because fusion of ubiquitin
to the chicken FANCD2 protein mutant for the lysine
acceptor allows complementation of chicken FANCD2
mutants but not FA mutants defective for the ligase activity
(Matsushita et al., 2005).
FANCD2 ubiquitination is critical for MMC resistance
and is required for the FANCD2 protein to form damage-
induced foci on chromatin (Garcia-Higuera et al., 2001).
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is not clear, but an important finding was that the FANCD1
gene is BRCA2, which has a known role in regulation of
Rad51-loading and homologous recombination (HR)
(Howlett et al., 2002).
Of all of the FA complementation groups, only FA-I
remains uncharacterized at the molecular level (Levitus
et al., 2004). FA-I mutant cells dot not ubiquitinate
FANCD2, precluding its localization to repair foci. Like
FA-D2 cells, FA-I cell lines have normal FA E3 ligase com-
plex formation (Levitus et al., 2004).
ATR appears to directly regulate the FA pathway. ATR is
required for monoubiquitination of FANCD2 (Andreassen
et al., 2004) and phosphorylates FANCD2 on several sites
required for FANCD2 function (Ho et al., 2006; Taniguchi
et al., 2002). In this study we provide new data supporting
a role for DNA-damage signaling in the FA pathway.
Through a proteomic screen for substrates for the ATM
and ATR kinases (S. Matsuoka et al., submitted) combined
with a DNA-damage sensitivity screen, we identified the
FANCI gene, which is mutated in FA-I cells. FANCI is
paralogous with FANCD2, is also monoubiquitinated on
a lysine critical for its function, and may be the second
critical FA ligase substrate. FANCI binds FANCD2 to form
the ID complex that loads onto chromatin in response to
DNA damage.
RESULTS
KIAA1794/FANCI Is a Phosphoprotein
KIAA1794/FANCI was identified as a protein whose phos-
phorylation was induced upon ionizing radiation (IR) treat-
ment (S. Matsuoka et al., submitted). In that study, SILAC
(reviewed in Mann [2006]) and peptide immunoprecipita-
tion (Rush et al., 2005) using phosphospecific antibodies
followed by mass spectrometry before and after DNA
damage was used to identify those proteins that were
inducibly phosphorylated on SQ or TQ motifs. Three phos-
phorylation sites were detected in a human KIAA1794
protein: S730, T952, S1121, and two other sites in the
mouse protein S555, T558. We renamed the KIAA1794
protein as FANCI since, as shown below, the locus
encoding this protein is mutated in an individual with
Fanconi anemia complementation group I. Immunoblotting
of FANCI after IR with a phospho-SQ antibody confirmed
its inducible phosphorylation (Figure 1A), thus placing it
in the ATM/ATR pathway.
Multicolor Competition Assay (MCA)
To efficiently study DNA-damage sensitivity of cells with
a variety of genetic perturbations, we developed a sim-
ple competition assay that is both quantitative and fast
(Figure 1B).Twopopulations of U2OS (osteosarcoma) cells
differing only in their color were created by expression of
red (RFP) or green (GFP) fluorescence protein. siRNA de-
pletion of the protein of interest was carried out in the green
cells, while the red cells were transfected with control
siRNA. Equal numbers of green and red cells were mixed,
left untreated, or treated with gamma irradiation or MMC.290 Cell 129, 289–301, April 20, 2007 ª2007 Elsevier Inc.After 7 days, cells were harvested and ratio of red-to-green
cells determined using flow cytometry. The green-to-red
ratio in untreated cells acted as a control for the relative
cell growth. The assay was validated using siRNAs target-
ing ATM (IR sensitivity) and ATR (MMC and IR sensitivity)
(Figures 1C and S1).
MCA was applied to study a subset of ATM and ATR
substrates (S. Matsuoka et al., submitted). Cells treated
with a combination of three siRNAs against one of the
tested proteins, FANCI (KIAA1794, a.k.a. FLJ10719),
demonstrated 60% survival after 70 nM MMC treatment
and 91% survival after 3Gy IR treatment relative to control
siRNA-transfected cells (data not shown). To exclude off-
target effects, three siRNAs were tested independently.
Two of three siRNAs reproduced the phenotype of MMC
sensitivity with only a slight effect on the IR sensitivity (Fig-
ure 1C). This decreased survival is due to a DNA repair
defect as metaphase spreads of primary fibroblasts trans-
fected with FANCI siRNA and treated with MMC revealed
frequent cytogenetic abnormalities including chromatid
and chromosome breaks as well as radial forms (Fig-
ure 1D), hallmarks of Fanconi anemia.
FANCI Displays Homology to FANCD2
BLAST analysis with FANCI revealed high conservation
among eukaryotes from human to Dictyostelium but not
yeasts and limited conservation to a predicted partial
S.purpuratus sequence similar to FANCD2 (Figure 2A).
The homology region extended over 151 amino acids
with 19% identity and 45% similarity. The coding region
of FANCI was amplified from a human lymphocyte cDNA
library (Elledge et al., 1991) and recovered an open reading
frame of 3984 nucleotides, coding for a 1328 aa protein
of a calculated molecular weight 150 kDa. This cDNA
corresponds to a putative splice variant isoform 3 of the
KIAA1794 (Q9NVI1) locus on chromosome 15q25-q26.
Alignment of FANCI and FANCD2 revealed a modest
13% identity and 20% similarity across the entire protein
(Figures 2B and S3). Comparable levels of similarity
were found between the FANCD2 and FANCI paralogs in
other species including A. thaliana and D. melanogaster.
The most striking conservation between FANCI and
FANCD2 throughout species surrounded K523 in FANCI
and K561 in FANCD2 (Figures 2B and 2C). This site has
been previously shown to be monoubiquitinated in
FANCD2 and to be essential for the functionality of the
FA pathway (Garcia-Higuera et al., 2001).
FANCI Participates in Cell-Cycle Checkpoints
and DNA Repair Pathways
As the ATM/ATR pathways control multiple cellular
responses, we asked if FANCI participates in cell-cycle
control, DNA synthesis control, or HR following DNA dam-
age. siRNA against FANCI abrogated the G2/M check-
point in U2OS cells (Figure 3A) and also had a small but
reproducible effect in the intra-S phase checkpoint
(Figure 3B). Interestingly, in unirradiated cells FANCI
depletion caused an increased basal level of damage as
Figure 1. Identification of the KIAA1794/FANCI Protein
(A) Western analysis with an antibody raised against a phosphorylated form of SMC3 (SMC3 pS1083) on immunoprecipitates performed with FANCI
antibody (BL999) from 293T extracts before and after DNA damage.
(B) Schematic of the multicolor competition assay (MCA). See text for details. In this example, the knockdown of a protein of interest caused the green
fluorescent protein (GFP) cells to become DNA-damage sensitive without influencing their proliferative capacity in the absence of damage. The
relative resistance to damage of the si-treated cells is 40% of the non-si-treated cells.
(C) MCA analysis in U2OS cells treated with siRNAs against ATM and ATR and three different siRNAs against FANCI.
(D) Cytogenetic abnormalities in IMR90 cells transfected with siRNA against FANCI or lacZ control and treated with 0, 5, or 7.5 ng MMC per ml.
Asterisk indicates a statistically significant difference in means as calculated by the t test. Experiment with 7.5 ng MMC per ml was performed once.judged by g-H2AX (Figure 3C) indicative of a role in main-
tenance of genomic stability.
The FA pathway has been previously implicated in HR
(Nakanishi et al., 2005; Niedzwiedz et al., 2004; Yamamoto
et al., 2005), and therefore we examined FANCI for a poten-
tial role in HR repair. DR-U2OS cells used in this assay (Xia
et al., 2006) have an integrated HR reporter. Induction of
a double-strand break, resulted in a robust repair as
indicated by the appearance of 12% GFP-positive cells
(Figure 3D). All four siRNAs to FANCI reduced recombina-
tion from 78% to 47% of controls, similar to siRNAs to
ATR, FANCA, and FANCD2 (Nakanishi et al., 2005) but
less than siRNAs to BRCA1 and BRCA2, which are thought
to be more directly involved in the recombination process
(Figures 3E and 3F). These results indicate that FANCI is an
important component of the HR-repair pathway.
FANCI Localizes to Damage-Induced Foci inMultiple
Cell Types
To assess FANCI localization, immunofluorescence ex-
periments were performed on transformed (U2OS, HeLa,and 293T) and primary (BJ) cell lines. Analysis using two
antibodies BL999 and BL1000 revealed foci in a subset
of untreated cells and in nearly all cells after DNA damage.
In some experiments, a nuclear rim staining was also
detected. These FANCI foci corresponded to damage-
induced foci as they colocalize with FANCD2 staining
(Figure 4A) (Garcia-Higuera et al., 2001). Confirmation of
the antibody specificity was achieved using transfected
Myc-FANCI and anti-Myc antibodies (Figure S4A).
siRNA-treated cells showed decreased damage-induced
foci staining with BL999 and BL1000 antibodies after
Triton-X pre-extraction (data not shown).
FANCI and FANCD2 Form a Complex Required for
FANCD2 Localization to Damage-Induced Foci
Depletion of FANCI in U2OS using three separate siRNAs
resulted in diminished ubiquitination of FANCD2 upon
damage (Figure 4C), and the loss of this modification
corresponded to a prominent reduction in FANCD2 signal
at damage-induced foci as well as appearance of cells
with no visible FANCD2 foci (Figure 4B). Moreover, theCell 129, 289–301, April 20, 2007 ª2007 Elsevier Inc. 291
Figure 2. Identification of Evolutionarily Conserved Regions of KIAA1794/FANCI
(A) A BLAST alignment identifying human KIAA1794 conservation with a portion of the Strongylocentrotus purpuratus (S.p.) ortholog of FANCD2.
A star indicates the lysine corresponding to K561 in FANCD2.
(B) Alignment of FANCI and FANCD2 identifies a conserved lysine K523.
(C) Schematic of FANCI and FANCD2. Highlighted are two regions predicted by the SCOP database (Murzin et al., 1995) as ARM repeats which
represent alpha-alpha superhelix folds (amino acids [aa] 985–1207 in FANCI and aa 267–1163 in FANCD2) and a lipocalin fold (aa 612–650), which
is predicted to bind hydrophobic ligands in its interior. Also shown is putative bipartite NLS (aa 779–795) identified in FANCI. Red stars indicate
phosphorylation sites identified in human or mouse proteins (S. Matsuoka et al., submitted). Black stars indicate the ATR sites in FAND2. The
EDGE sequence is also conserved between the proteins. An arrowhead indicates the disease-causing mutation in a cell line of Fanconi anemia
complementation group I (see Figure 6).steady-state level of FANCD2 was decreased upon deple-
tion of FANCI (Figure 4C). There was also a reciprocal
relationship between FANCD2 and FANCI, since the
knockdown of FANCD2 also led to decreased foci forma-
tion of FANCI (Figure S4B, top panel). Loss of FANCD2
upon depletion of FANCI might be expected if the two
proteins are found in a complex. Immunoprecipitation of
HA-FLAG-tagged FANCI expressed in 293T cells with
antibodies against either HA or FLAG, but not MYC, re-
sulted in coimmunoprecipitation of endogenous FANCD2
(Figure S4C). The interaction was independent of DNA
damage and was robust with 15%–20% of total FANCD2
immunoprecipitated. Immunoprecipitation of endogenous
FANCI was also able to coimmunoprecipitate FANCD2
(Figure S4D) and immunoprecipitation with FANCD2 anti-
bodies recovered FANCI (Figure S4E). To test if monoubi-
quitination of FANCD2 was required for this interaction,
PD20 cells complemented with wild-type (wt) or the
K561R mutant of FANCD2 that cannot be monoubiquiti-
nated (Garcia-Higuera et al., 2001) were used in immuno-
precipitation experiments. Immunoprecipitation of HA-
FLAG-tagged FANCI expressed in these cells recovered
both wt and the K561R mutant FANCD2 (Figure 4D, lanes
5 and 8) suggesting that ubiquitination of FANCD2 is not
required for the interaction with FANCI.
FANCI Becomes Ubiquitinated after Damage
and during an Unperturbed S Phase
Presence of the conserved lysine in FANCI at a position
corresponding to the FANCD2 ubiquitination site raised
the possibility that FANCI is also ubiquitinated. Indeed,292 Cell 129, 289–301, April 20, 2007 ª2007 Elsevier Inc.a slower migrating band was present on the western blots
performed with two nonoverlapping anti-peptide anti-
bodies in U2OS cells (Figure 5A) as well as in other cell
lines including primary BJ fibroblasts (Figure 5 and data
not shown). The slower migrating band (long form, L),
although present in the untreated cells, increased after
DNA damage inflicted by MMC (Figure 5A) or hydroxyurea
(HU) (Figures 5G and 5H). The molecular weight difference
between the long form and the short form (S) is consistent
with monoubiquitination. To test this, FANCI was immuno-
precipitated from 293T cells expressing HA-tagged ubiq-
uitin and immunoblotted with HA-antibodies (Figure 5B).
A band of appropriate size was identified corresponding
to the long form of FANCI only in cells transfected with
HA-tagged ubiquitin but not in control cells. To exclude
the possibility that the monoubiquitinated protein seen
in Figure 5B is a FANCI-associated protein, pull-downs
from HeLa extracts expressing His-biotin ubiquitin were
performed with Streptavidin under fully denaturing condi-
tions (Tagwerker et al., 2006). Wt but not K523R FANCI
mutant (see below) precipitated under these conditions
(Figure 5C). Therefore, both, FANCI and FANCD2 are
monoubiquitinated in vivo.
Chromatin fractionation experiments revealed that the
ubiquitinated form of FANCI, like FANCD2 (Montes de
Oca et al., 2005), is enriched in chromatin (Figure 5D).
To ask whether FANCI is modified during the cell cycle,
U2OS cells were synchronized and released from a mitotic
block. Cells in mitosis and the G1 phase of cell cycle
lacked ubiquitinated FANCI or FANCD2 (Figure 5E). By
9 hrs after release, when most cells were in early S phase,
Figure 3. Checkpoint and Repair Defects in Cells with Reduced Levels of FANCI
(A) Cells depleted for FANCI have checkpoint defects. U2OS cells were treated as shown in the schematic. Two separate fields of cells were exam-
ined. The mean and standard deviation from two fields are shown. Average of 1000 cells per siRNA were scored.
(B) Effects of FANCI depletion on radioresistant DNA synthesis. U2OS cells transfected with the indicated combination of three different siRNAs were
irradiated with 5Gy or 10Gy of IR depending on an experiment, allowed to recover for 30 minutes and assayed in triplicate for DNA synthesis. The
means and standard deviations of four separate experiments are shown. For comparison, IR treatment of the ATM siRNA-transfected cells causes
DNA synthesis to be 70%–80% of the level found in the untreated cells.
(C) Reduction of FANCI causes spontaneous DNA damage. U2OS cells transfected with the indicated combinations of three different siRNAs were
collected 3 days later, and the level of g-H2AX was assayed without inflicting any exogenous damage. Western analysis with Ran antibody acted as
a loading control.
(D) Flow cytometric analysis of DR U2OS cells uninfected or infected with the AdNgus24i adenovirus carrying I-SceI (I-SceI-Ad) or AdCA36 carrying
b-galactosidase (b-gal-Ad). Infections were carried out at a multiplicity of infection of 5, and analysis for GFP-positive cells was performed at 36 hrs
after infection.
(E and F) FANCI is required for HR. In (E), DR U2OS cells were transfected with the indicated combination of three different siRNAs and 3 days later
were infected with 10 pfu/cell of adenovirus carrying I-SceI. Flow cytometric analysis of GFP-positive cells was carried out 36 hrs after infection. Mean
and standard deviation of eight experiments (ATM), seven experiments (ATR), four experiments (Brca2), and three experiments (FANCI) are shown.
In (F), DR U2OS cells were transfected with the indicated RNAs, infected with 5 pfu/cell of adenovirus carrying I-SceI (AdNgus24i) and analyzed
24 hrs later.FANCI appeared ubiquitinated. Since the experiment was
done in the absence of exogenous damage, we conclude
that endogenous FANCI is modified in an unperturbed
S phase.Ubiquitination of FANCI Is FANCA and FANCD2
dependent
To search for the E3 ubiquitin ligase for FANCI, we exam-
ined FANCI modification in FANCA mutants defective forCell 129, 289–301, April 20, 2007 ª2007 Elsevier Inc. 293
Figure 4. FANCI Localizes and Interacts with FANCD2
(A) Localization of the endogenous FANCI using BL999 and BL1000 antibodies. U2OS cells treated with 1 mM MMC for 24 hr were Triton-X-extracted
before costaining with anti-FANCI (BL999 or BL1000) and anti-FANCD2 antibodies.
(B) Localization of FANCD2 in cells transfected with individual siRNAs against FANCI. U2OS cells were transfected with the indicated individual
siRNAs against FANCI and treated with 1 mM MMC. Twenty-four hours later, following Triton-X extraction, the cells were costained with an antibody
against FANCD2 and H2AX.
(C) Western analysis of FANCD2 in U2OS cells transfected with individual siRNAs against FANCI. L is the long (monoubiquitinated) and S is the short
form of the proteins. Asterisk indicates crossreacting band.
(D) Interaction of FANCD2 and FANCI. Total protein (0.5 mg) from PD20 fibroblasts expressing indicated constructs was immunoprecipitated with
FLAG or control Myc antibodies under nondamaged conditions. The immunoprecipitates were analyzed by western blotting with a rabbit anti-
FANCD2 or mouse anti-HA antibody.the core E3 ligase complex. FA-A cells GM6914 cells lack-
ing FANCA showed no ubiquitination of the endogenous
or HA-tagged FANCI (Figure 5F; lanes 1, 2, 5, and 6), but
ubiquitination was restored after complementation with
wt FANCA (Figure 5F; lanes 3, 4, 7, and 8).
FANCD2 and FANCI show reciprocal ubiquitination
dependencies. PD20 fibroblasts, which lack FANCD2
(Jakobs et al., 1996), when transfected with the ubiquitina-
tion-defective FANCD2 K561R mutant also fail to ubiquiti-
nate FANCI (Figure 5G, lanes 3 and 4). The same cells
complemented with wt FANCD2 restore FANCI modifica-
tion (Figure 5G, lanes 5 and 6). PD20 cells expressing wt or
K561R FANCD2 also showed increased levels of FANCI
(Figure 5G), consistent with the notion that the nonubiqui-
tinated forms of the proteins bind constitutively in a heter-
odimeric (or multimeric) Fanconi anemia ID complex.
USP1 is the deubiquitinating enzyme for FANCD2 (Nijman
et al., 2005). To test whether USP1 also can affect FANCI
monoubiquitination, HeLa cells were transfected with
siRNA against USP1. Reduction of USP1 increased the294 Cell 129, 289–301, April 20, 2007 ª2007 Elsevier Inc.L to S ratio for both FANCI and FANCD2 under basal
conditions and after HU treatment (Figure 5H).
Lysine 523 of FANCI Is Critical for Its Ubiquitination
To determine whether the conserved lysine 523 of FANCI
was required for ubiquitination, a wt or K523R mutant
HA-tagged FANCI were stably expressed in GM6914
(Figure 5F) and in 293T cells (Figure S5A). Only in cells
that expressed the wt FANCI but not the K523R mutant
was the L form detected with the HA antibody (Figures 5F
[lanes 7, 8, 11, and 12] and S5A). Interestingly, cells over-
expressing the FANCI K523R mutant, but not wt, showed
diminished monoubiquitination of FANCD2 (Figures 5F
[lanes 11 and 12] and S5A), suggesting that the mutant
FANCI displays a dominant-negative activity.
Consistent with the role of FANCI in ubiquitination of
FANCD2, the FANCI K523R mutant failed to form DNA
damage foci (Figure 5I; + Triton) despite its overproduc-
tion (data not shown). Cells expressing K523R FANCI
allele showed pan-nucleoplasmic FANCD2 staining and
Figure 5. FANCI Ubiquitination and Its Dependence on Fanconi Anemia Pathway
(A) Western blot analysis of FANCI in U2OS cells. U2OS cells were treated with 1 mM MMC, and 24 hr later, cells were lysed directly in 23 Laemmli
buffer. Long (L) and short (S) forms of FANCI are shown. The asterisk indicates a crossreacting band.
(B) In vivo ubiquitination of FANCI. Whole cell extracts of 293T cells transiently transfected with HA-tagged ubiquitin or control plasmid carrying dsRed
marker were immunoprecipitated using antibodies raised against FANCI and analyzed by western blot with a FANCI antibody (left) and antibody
recognizing the HA tag (right).
(C) In vivo ubiquitination of FANCI. HeLa cells expressing ubiquitin tagged with His and a biotynylation signal were treated with 2 mM HU for 16 hrs,
lysed in 8 M urea, and precipitated using Streptavidin beads under denaturing conditions.
(D) Chromatin fractionation of FANCI in U2OS cells. Cells were treated with 1 mM MMC and 24 hrs later cells were collected and processed into cellular
fractions. Whole cell extract (WCE), cytoplasmic proteins (S1), intact nuclei (P1), soluble nuclear proteins (S2), chromatin-enriched pellet (P2), and
soluble and insoluble fractions after micrococcal nuclease treatment (S20 and P20) are indicated. Orc2 antibody was used to follow the chromatin
fraction.
(E) Cell-cycle analysis of FANCI ubiquitination. After release from nocodazole, cells were collected at indicated times for the western analysis (top
panel) and for cell-cycle analysis using flow cytometry (lower panel).
(F) Analysis of ubiquitination in GM6914 (FA-A) fibroblasts. Cells expressing vector or wt FANCA were stably transduced with empty vector, or
HA-tagged wt FANCI. Twenty-four hours after 1 mM MMC treatment cells were collected, and western blotting was performed with the indicated
antibodies.
(G) Analysis of ubiquitination in PD20 (FA-D2) fibroblasts. Cells expressing vector, K561R mutant, or wt FANCD2 were treated with 2 mM HU and
collected 15 hrs later. Western blotting was performed with the indicated antibodies, including FANCD2 antibody to confirm absence (lanes 1 and
2) or presence (lanes 3, 4, 5, and 6) of FANCD2 protein. The asterisk indicates a crossreacting band.
(H) Ubiquitination of FANCD2 and FANCI in HeLa cells transfected with siRNA against USP1 and lacZ control, treated with 2 mM HU, and collected
15 hrs later. L/S indicates the ratio of the monoubiquitinated to nonubiquitinated FANCI or FANCD2.
(I) Localization of FANCI and FANCD2 in wt and K523R FANCI-expressing U20S cells. Cells stably transduced with the HA-tagged wt or K523R
mutant allele of FANCI were treated with 1 mM MMC and processed 24 hrs later for immunofluorescence. Note that cells not expressing K523R in
the lower panels (K523R  Triton) are included as controls for FANCD2 staining. Two FANCD2-positive cells in the lower right panel (+ Triton) are
presumed not to have K523R FANCI expression, although that cannot be tested directly since Triton-X removes nucleoplasmic FANCI. Similar
results were observed in U2OS cells expressing the K523R mutant treated with HU.Cell 129, 289–301, April 20, 2007 ª2007 Elsevier Inc. 295
greatly diminished localization to DNA damage-induced
foci best visualized after Triton-X pre-extraction (Figure 5I).
These data show that the K523R mutant has a dominant-
negative effect on FANCD2 foci formation.
FANCI Is Mutated in Cells from the Fanconi Anemia
Complementation Group I
Phenotypic similarities of cells with reduced levels of
FANCI to cells from Fanconi anemia patients, including
marked MMC but only mild IR sensitivity (Figure 1B),
alerted us to the possibility that mutations in FANCI might
be responsible for human disease. Published reports
included only one remaining complementation group for
which the responsible gene was unknown, Fanconi anemia
complementation group I (Levitus et al., 2004). We worked
with one of the cell lines from this group, BD0952, Epstein
Barr Virus-transformed peripheral lymphocytes from a
patient with a classic presentation of Fanconi anemia.
BD0952 express a full-length FANCI protein at normal
levels relative to control cells (GM03288) (Figure 6A). How-
ever, this protein is not ubiquitinated in BD0952 cells, even
after MMC treatment (Figure 6A and data not shown).
FANCD2 is not ubiquitinated in FA-I cells (Figure 6A)
(Levitus et al., 2004), thus restoration of FANCD2 ubiquiti-
nation acts as a surrogate marker for the functional com-
plementation of the Fanconi anemia pathway. Expression
of the FANCI cDNA in BD0952 cells restored FANCD2
ubiquitination (Figure 6A). This exogenous FANCI was
also monoubiquitinated (Figures 6A and S5B). Appear-
ance of the monoubiquitination was not due to changes
in the cell cycle of the cells expressing FANCI
(Figure S5C). Also, the levels of expression of the exoge-
nous proteins were comparable to the endogenous
protein (compare tagged [T] versus endogenous [E],
Figures 6A and Figure S5B). Expression of wt FANCI in
BD0952 also complemented their MMC resistance to wt
levels (Figure 6B).
To look for FANCI mutations in BD0952 cells, we am-
plified and sequenced the cDNA from BD0952 mRNA
and found two base substitutions as candidates for the
Fanconi anemia-causing mutation in BD0952 cells. They
included a C to T transition, which resulted in Pro to Leu
change at amino acid 55, and a G to A transversion, which
resulted in Arg to Gln substitution in an absolutely con-
served Arg1285 at the C terminus of the protein. We
confirmed these mutations by amplifying exon 3 and
exon 36 from genomic DNA. Sequencing confirmed pres-
ence of both mutations in genomic DNA in homozygous
form (Figure 6C). Homozygosity was expected at the
disease locus since the patient comes from a consanguin-
eous family with both parents expected to contribute the
disease allele of FANCI to their child.
To test which mutation causes the disease, we made
expression constructs containing P55L, R1285Q, and
P55L-R1285Q substitutions. Only the wt and the P55L
allele were able to complement the FANCD2 monoubiqui-
tination defect (Figure 6D) and MMC sensitivity (Figure 6E)
of BD0952 cells. These two proteins were also themselves296 Cell 129, 289–301, April 20, 2007 ª2007 Elsevier Inc.monoubiquitinated in BD0952 cells. When introduced into
U2OS cells or into BD0952 cells, the P55L allele was found
in foci together with FANCD2 (Figures 7A and S6). Cells
expressing R1285Q or P55L-R1285Q alleles showed no
monoubiquitination of FANCD2 (Figure 6D) and failed
to restore MMC resistance (Figure 6E). Unlike wt FANCI
allele, which could complement breakage phenotype
seen in BD0952 cells, the R1285Q allele-expressing cells
showed a high number of aberrations after treatment
with MMC (Figure 6F). When introduced into U2OS or
BD0952 cells, the R1285Q or P55L-R1285Q alleles failed
to localize to damage-induced foci (Figures 7A [+ Triton
panel] and S6) despite robust expression levels of the mu-
tant proteins as judged by the immunofluorescence stain-
ing in the absence of triton extraction (Figure 7A;  Triton
panel). Together, these studies indicate that the R1285Q
change is the disease-causing mutation in BD0952 cells.
Unexpectedly, we found the K523R FANCI allele was
able to partially complement the FANCD2 monoubiquitina-
tion defect (Figure 6A; lanes 7 and 8) and MMC sensitivity
defect in BD0952 cells (Figure 6F). This is in contrast to the
findings that FANCI K523R mutant fails to be ubiquitinated
or form damage-induced foci and that K523R allele when
overexpressed acts as a dominant negative against
FANCD2 ubiquitination and foci formation. These results
suggest either that this allele is only partially defective or
more likely that it is displaying interalleleic complementa-
tion with the FANCI R1285Q mutant present in BD0952
cells. Further studies will be needed to resolve this issue.
DISCUSSION
The response to DNA damage and DNA replication stress
is orchestrated by the ATM and ATR kinases that direct
the phosphorylation of key proteins that carry out this
stress response. Knowledge of their substrates is key to
both identifying and elucidating DNA repair responses.
In this study we examine one such recently identified sub-
strate of these kinases (S. Matsuoka et al, submitted), the
KIAA1794 protein, which we discovered to be encoded by
the FANCI gene.
FANCI Is a FANCD2 Paralog Required for Crosslink
Repair
FANCI depletion caused a phenotype consistent with
a role in DNA crosslink repair. FANCI is highly conserved
from humans to Dictyostelium, but absent in budding
and fission yeast. The interior of FANCI, like that of
FANCD2, is composed of ARM repeats that fold into
superhelical helices, suggesting that these proteins have
an extended structure. A crucial finding was a short
stretch of similarity to Sea Urchin FANCD2, a central com-
ponent of the Fanconi anemia pathway. This conserved
region contained a key lysine known to be monoubiquiti-
nated in FANCD2 that is critical for FANCD2 function.
FANCI contains a weak but significant similarity through-
out the length of the human FANCD2 protein. As FANCI
and FANCD2 are approximately the same size, show
Figure 6. Complementation of BD0952 (FA-I) Cells with the KIAA1794/FANCI cDNA
(A) Complementation of FANCD2 ubiquitination defects in FA-I cells by expression of wt FANCI. Cells stably transduced with empty vector, HA-
tagged wt, or K523R FANCI were untreated or treated with 100 nM MMC and collected 24 hrs later by lysis in Laemmli buffer. Western analysis
with FANCD2, FANCI, and HA antibodies was performed. GM02188 (wt control) cells acted as a control for the presence of long (L, ubiquitinated)
forms of FANCD2 and FANCI, which are absent in the uncomplemented BD0952 cells. The transduced form of the protein is identified as T (tagged),
since it runs slightly slower than the endogenous (E) form. Also see Figure S5B.
(B) Complementation of MMC sensitivity of BD0952 cells by expression of wt FANCI but not empty vector. Logarithmically growing cells of indicated
genotypes were treated in triplicate with different levels of MMC ranging from 0 to 100 nM. They were allowed to grow for 6 days, at which time they
were harvested, and total cell number was counted using a coulter counter. Total cell numbers at each dose were divided by the number of cells in the
untreated sample to arrive at percent survival.
(C) Sequence analysis of the FANCI genomic locus in BD0952 (FA-I) cells. Sequence of the genomic contig (refjNT_010274.16jHs15_10431:4714523-
4889523 Homo sapiens chromosome 15 genomic contig, reference assembly) and sequence traces of genomic DNA from BD0952 cells are shown
together with the resulting amino acid sequence deduced from the DNA sequence data.
(D) Complementation of FANCD2 ubiquitination by expression of wt FANCI or P55L FANCI, but not R1285Q or P55L-R1285Q FANCI mutants. Cells
stably transduced with the indicated alleles of FANCI were left untreated or were treated with 100 nM of MMC and processed 24 hrs later as indicated
in (A).
(E) Complementation of MMC sensitivity of BD0952 cells by expression of WT FANCI or P55L FANCI, but not R1285Q or P55L-R1285Q FANCI
mutants. Experiments were done as indicated in (B). MMC treatments were done in triplicate and the mean and standard deviation is shown.
(F) Cytogenetic abnormalities in BD0952 cells expressing wt, K523R, or R1285Q FANCI alleles. Indicated cells were treated with 0, 20, or 40 ng
MMC per ml of media and analyzed for presence of chromosomal aberrations 48 hrs later. K523R mutant was not assessed at 20 ng of MMC per
ml. Analysis was done only once at 40 ng of MMC per ml. Thirty to fifty metaphases were evaluated for each cell line.similarity along their length, and both have an extended
region of superhelical ARM repeats, it is likely that these
proteins were derived from a common ancestral gene
duplication event and subsequently diverged through
evolution to produce two functionally distinct paralogs.FANCI Is Mutated in FA-I Cells
As KIAA1794/FANCI showed characteristics of a Fanconi
anemia protein we anticipated that previously unassigned
Fanconi patients might harbor mutations in our gene.
We were able to obtain BD0952 cells from the FA-ICell 129, 289–301, April 20, 2007 ª2007 Elsevier Inc. 297
Figure 7. Localization of Mutant FANCI Alleles
(A) Localization of wt, P55L, R1285Q, and P55L-R1285Q mutant proteins in U2OS cells. U20S cells transduced with the indicated alleles of FANCI
were treated with 100 nM MMC, and 24 hrs later, were processed for immunofluorescence.
(B) Model of Fanconi anemia ID complex regulation and function. The phosphorylation-ubiquitination cascade culminates in chromatin loading of the
Fanconi anemia ID complex, which directs downstream repair events.complementation group. FA-I cells are MMC sensitive and
fail to monoubquitinate FANCD2 or form FANCD2 foci in
response to DNA damage. Retrovirally expressed FANCI
complemented FA-I mutants for all three phenotypes.
DNA-sequence analysis revealed two amino acid changes
in the FANCI protein. Complementation analysis reveals
that the R1285Q mutation is responsible for the defect in
BD0952 cells and fails to restore MMC resistance and
FANCD2 regulation. The R1285Q mutation is present in
both copies of FANCI in these cells consistent with family
consanguinity. The complementation, coupled with the
identification of inactivating mutations in BD0952 cells,
unambiguously identifies KIAA1794 as the FANCI gene.
Preliminary analysis revealed a candidate causative muta-
tion, C3853T, in a second FA-I cell line, EUFA816, result-
ing in conversion of the essential R1285 to a stop codon
(A.S. and S.J.E., unpublished data), further highlighting
the importance of the C terminus of FANCI for its function.
FANCI in the other FA-I cell lines (Levitus et al., 2004)
remains to be examined for the presence of mutations to
confirm the cell-fusion data that placed them in the
same complementation group as BD0952 cells.298 Cell 129, 289–301, April 20, 2007 ª2007 Elsevier Inc.FANCI Is Monoubiquitinated
Like FANCD2, FANCI has a slower migrating form that
several lines of evidence suggest is due to monoubiquiti-
nation. First, the key lysine responsible for FANCD2
ubiquitination is conserved in FANCI. Secondly, FANCA
mutant cells defective for the FA ubiquitin ligase complex
fail to generate the slower migrating form. Third, mutation
of this lysine, K523R, in FANCI prevents formation of the
slower migrating form. Finally, FANCI antibodies specifi-
cally immunoprecipitate epitope-tagged ubiquitin cova-
lently attached to FANCI. Like FANCD2, the ubiquitinated
form of FANCI is enriched on chromatin and the K523R
FANCI mutant does not get loaded onto chromatin. The
significance of FANCI monoubiquitination is illustrated
by the fact that the K523R mutant of FANCI does not itself
become monoubiquitinated and does not form damage
foci. When introduced into U2OS cells, which express
a wt FANCI allele, this mutant reduced FANCD2 monoubi-
quitination and foci formation. Furthermore, the K523R
mutant fails to fully complement FANCD2 ubiquitination
or MMC sensitivity of BD0952 cells, indicating that ubiqui-
tination is important for FANCI function. As this line is not
a null mutant, it is possible that this intermediate FANCD2
monoubiquitination and MMC-resistance phenotype might
represent interallelic complementation.
FANCI and FANCD2 Form an Interdependent ID
Complex that Is Required for Ubiquitination
and Chromatin Association
We anticipated that FANCI would associate with FANCD2
because FANCI protein formed foci that colocalized with
FANCD2; depletion of FANCI significantly reduced the
monoubiquitination of FANCD2, preventing its inclusion
into DNA damage-induced foci; and FA-I cells have
completely lost their ability to monoubiquinate FANCD2
despite fully formedFAcomplex (Levitusetal., 2004). Indeed,
FANCI forms a complex with FANCD2, with approximately
20% of FANCD2 coimmunoprecipitating with tagged
FANCI protein. The FANCI-FANCD2 complex, which we
propose to call the Fanconi anemia ID complex, thus joins
the Fanconi anemia core complex as a new downstream
complex necessary for interstrand crosslink repair and HR.
Just as the FANCI protein monoubiquitination is re-
quired for FANCD2 ubiquitination and foci formation,
FANCD2 and FANCD2 ubiquitination are required for
FANCI ubiquitination. Thus, these two paralogs are inter-
dependent and employ a dual ubiquitination mechanism
to affect downstream effector function. Furthermore,
phosphorylation of FANCD2 is required for its own efficient
ubiquitination and therefore for the efficient ubiquitination
of FANCI. By extension, FANCI phosphorylation is also
expected to be an essential event for the FA pathway follow-
ing DNA damage and during normal S phase progression.
This phosphorylation-ubiquitination cascade culminating
in chromatin loading of the ID complex offers an exquisite
control at sites of stalled forks. The ID complex, when
correctly placed, can direct repair pathways to remove
the crosslinks and repair the DNA so that replication can
resume and cells can survive. Without this key event, cells
are prone to genomic instability that can lead to increased
cell death, stem cell depletion, and tumorigenesis.
Among the key questions that remain to be answered is
how the ID complex is recognized for ubiquitination. Is it
directly ubiquitinated by the FANCL ligase complex, or is
there a more complex relationship among different ligases
converging on this pathway? What is the function of ID
ubiquitination, and why must both components be mono-
ubiquitinated? Is it merely required for chromatin loading,
or does it direct repair in the same way that proliferating
cell nuclear antigen ubiquitination directs repair? Does it
represent a ubiquitin code that directs specific repair
pathways? The identification of FANCI and the Fanconi
anemia ID complex should now allow these issues to be
approached with greater clarity.
EXPERIMENTAL PROCEDURES
Cell Lines
Complemented cell lines PD20 and GM6914 were described
previously (Taniguchi et al., 2002), and DR-U2OS were provided byMaria Jasin (Xia et al., 2006). GM02188 was obtained from Coriell,
BD0952 from European Collection of Cell Cultures (www.ecacc.org.
uk), and U20S from American Cell Culture Collection (ATCC).
Antibodies
Antibodies were as follows: KIAA1794; BL999 and BL1000 (Bethyl);
rabbit FANCD2 (Novus); mouse FANCD2 (Santa Cruz); FANCA (Rock-
land); ORC2 (BD Bioscience); Vinculin (Sigma); HA (Covance); MYC
(Covance); SMC3pS1083 (Bethyl); PhosphoH3 (Upstate); Ran (BD
Bioscience); gH2AX (Upstate). For the IPs, we used anti-HA affinity
matrix (Roche), anti-FLAG M2 agarose (Sigma), c-MYC (Santa Cruz)
and Protein A/G PLUS-Agarose (Santa Cruz). Secondary antibodies
for immunofluorescence (IF) were from Molecular Probes and Amersham
and for western blots were from Jackson Laboratory.
FANCI Cloning
PCR was performed using Platinum Taq DNA polymerase high fidelity
(Invitrogen) on a human cDNA library (Elledge et al., 1991). The total
RNA from BD0952 cells was isolated using Trizol (Invitrogen). The
RNA was reverse transcribed with Superscript III (Invitrogen) and dT
primers. The PCR step was performed using Platinum Pfx DNA poly-
merase (Invitrogen). Genomic DNA was prepared using DNeasy tissue
kit (Qiagen). See Supplemental Experiemental Procedures for primer
sequences.
Mutagenesis
The QuikChange II XL site-directed mutagenesis kit (Stratagene) or
QuikChange multisite-directed mutagenesis kit (Stratagene) was
used to make mutation in FANCI. See Supplemental Experiemental
Procedures for primer sequences.
siRNAs
Stealth siRNAs (Invitrogen) were transfected using Oligofectamine
(Invitrogen) at a final concentration of 85 nM total siRNAs. Assays
were done 48–72 hrs after transfection. Unless indicated otherwise,
combination of three siRNAs against the same gene were used. siRNAs
used in experiments shown in Figures 1D, 5G, and 5H were purchased
from Qiagen. In these experiments, cells were transfected at con-
centration of 20 nM using Hyperfect according to manufacturer’s
instructions. See Supplemental Experiemental Procedures for siRNA
sequences.
Immunofluorescence
Cells grown on autoclaved cover slips were processed as described in
the Supplemental Experiemental Procedures. For the IF on lympho-
blastic cell lines, coverslips were treated with sterile poly-D-lysine
hydrobromide, molecular weight > 300,000 (Sigma), and the cells
were allowed to attach for several hours.
Chromatin Fractionation and Immunoprecipitations
Chromatin fractionation was preformed as described (Mendez and
Stillman, 2000; Zou et al., 2002). Benzonase (Novagen) was included
in immunoprecipitation reactions. Details may be found in Supplemental
Experiemental Procedures.
MCA
SiRNA transfections were performed as described above with green
fluorescent protein (GFP) cells being transfected with a control siRNA
(luciferase) and red fluorescent proteins (RFP) cells with an siRNA of in-
terest. On day 3 after transfections, GFP and RFP cells were counted
and mixed in 1:1 ratio and were left untreated or were treated with IR or
MMC. After 7 days of culture, all cells were collected and analyzed
using Cytomix FC500 analyzer (Beckman Coulter). Relative survival
of Luc siRNA-treated cells after damage was set to 100%.Cell 129, 289–301, April 20, 2007 ª2007 Elsevier Inc. 299
G2/M Checkpoint Assay
U2OS cells were transfected with individual siRNAs for 3 days in a 96-
well format. Cells were irradiated with 5 Gy and allowed to recover for
1 hr before the addition of 100 ng nocodazole per ml of media to trap
cells that bypass the G2/M checkpoint. Cells were fixed and stained
with an antibody against Phospho-H3 9 hrs after irradiation.
Radioresistant DNA Synthesis Assay
Radioresistant DNA synthesis assays to evaluate the intra-S phase
checkpoint were done as described previously (Silverman et al.,
2004). For details see Supplemental Experiemental Procedures.
HR Assay
HR assay was performed as described (Nakanishi et al., 2005; Xia
et al., 2006), except instead of transfecting cells with an I-SceI-
expressing plasmid, we used an adenovirus AdNGUS24i (kindly pro-
vided by Frank Graham, McMaster University) expressing the I-SceI
enzyme. Control adenovirus AdCA36 (Addison et al., 1997) expressed
b-galactosidase.
Cell-Cycle Synchronization
U2OS cells were treated with 2.5 mM thymidine for 24 hrs, washed
three times and released into 100 ng nocodazole per ml of media, incu-
bated for 12 hrs, and collected by mitotic shakeoff. Cells were washed
three times, counted, and plated for collection at different times.
MMC Sensitivity Assay
Logarithmically growing cells were counted and diluted to 2x105 cells
per ml, plated in triplicate for each drug dose and treated with different
concentrations of freshly made MMC. After 6 days in culture, cells
were harvested and counted using a Z2 Coulter Counter (Beckman
Coulter). Cell numbers in the samples treated with the drug were
normalized to the cell numbers in the untreated sample.
Bioinformatics
BLAST was used for homology searches (http://www.ncbi.nlm.nih.
gov/BLAST/) (Altschul et al., 1997). The SCOP database can be found
at http://scop.mrc-lmb.cam.ac.uk/scop/ (Murzin et al., 1995). Align-
ments were performed in ClustalX and were rendered using ESPript
2.2 (http://espript.ibcp.fr) (Gouet et al., 1999).
Supplemental Data
Supplemental Data include six figures and Supplemental Experimental
Procedures and can be found with this article online at http://www.cell.
com/cgi/content/full/129/2/289/DC1/.
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